PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesTrial watch - inhibiting PARP enzymes for anticancer therapyDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsMVP and vaults: a role in the radiation responseGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasTherapeutic targeting of cancers with loss of PTEN function.Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitroUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicAnti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsStrategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.BRCAness profile of sporadic ovarian cancer predicts disease recurrence.PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.Evolutionary pathways in BRCA1-associated breast tumors.Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.Hiding in the dark: uncovering cancer drivers through image-guided genomics.Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.An update on PARP inhibitors for the treatment of cancerNanoparticle-mediated measurement of target-drug binding in cancer cellsDevelopment of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.Personalized therapy in endometrial cancer: challenges and opportunities.The genomics and genetics of endometrial cancer.Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.Potential Therapeutic Targets in Uterine Sarcomas.Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatmentRetinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progressionRational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowA tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsHarnessing synthetic lethal interactions in anticancer drug discoveryNew perspectives on molecular targeted therapy in ovarian clear cell carcinoma.
P2860
Q21129302-E4AAF649-5119-44F7-B6CC-B965F9CFF714Q26745673-B407FAE8-479E-47C0-A98C-0A28A93342F0Q26776513-64DD9F35-41C0-4C42-964D-6ABB6FBF3C50Q26852274-F9FF7D43-17FA-4042-BA17-0C6C8EE9842FQ26865123-9E0849C9-5726-4E92-94FE-620024678BEAQ27852671-D4C8BF56-3948-4377-A09B-B8B46F704848Q27852764-140BC5CC-D1E1-4F01-A15A-8B703CDD1860Q27853018-99A71FC6-1FEA-4D55-BB6F-E3B2FDC9BF69Q28071541-4A4BCA70-DB97-4974-961C-41B55BF3FF4CQ33557916-963B04F2-2AF0-4DD9-850C-15CE77002E3CQ33579776-8CF89664-A093-473C-97F1-72897B313182Q33599105-BFD66466-AEF9-40AF-962E-434D0EEBF51FQ33618910-BEFA4126-1A4F-4B9B-B0B3-0B1D77B6F900Q33649555-DD03B3A3-6EF0-42CE-BEFB-C1C0FB282937Q33917630-272F0366-31D0-4B17-9968-AC36B0DBAB2DQ34130956-D66AE3A9-392E-42D5-ADCA-B0B0E1B8F4BFQ34215904-F9D2C167-B360-4E65-AFF6-2594BDB6853AQ34277174-4D379B4A-3B61-4578-BB45-DBDA63A236CDQ34306540-B25AD076-A1A1-4BB0-9EBD-19BAF37CB3E5Q35030274-6DFBCF87-7847-450F-B5C5-D213C1366A72Q35051154-90F761A9-77A6-4DD5-9BE4-66903C24A2C8Q35051517-7E3A4D5A-B2EB-481C-9FE0-0E6A045DFA64Q35119267-9AA0A1FB-F1DE-4F3B-8964-05B91850031CQ35142718-7841F1AE-FDC2-4729-B20E-70299230BE9DQ35813733-1F81E4FD-148A-4DE2-8640-DB588EE5FF36Q35869645-CCB44F20-3FAD-45AA-8AB0-BC5F2F886B8EQ35895214-13CB1830-3BB2-4753-96EA-72DD09CBC19EQ35911350-B881EF48-ACC7-4C4C-8791-E510EE1AF310Q36151896-DB0555A0-280E-4CF3-BE88-B1471FF58B0FQ36195450-12E537E0-6F0C-467D-A132-D54F30019B90Q36245677-BB6ECBBF-68F7-4993-9C4C-691BDD65C546Q36245791-E7DFDE54-77F9-4DE2-9AD9-021AD7598E23Q36254394-F28939DF-3DC4-49F7-BC20-5184052D725DQ36294441-C6689C47-6B21-4FAD-9818-688E0452A0A2Q36693272-DF21A7FC-FA04-4D9F-A25E-88B67EF4F50EQ36727409-90F7CDC3-D79C-4F99-9E34-45BD096C7CADQ36731185-C1ECDFB9-5CC7-4841-BF4A-7E2F371B3668Q36740744-A9D1C1CA-65D6-4DF2-BBE0-90627E48E08CQ36839571-7C9C70CE-BE18-42E8-BFE0-6BAB0AAAD0FBQ36889642-93CE9002-5604-4D10-B2F8-48984D9E201B
P2860
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
PTEN deficiency in endometrioi ...... ensitivity to PARP inhibitors.
@en
PTEN deficiency in endometrioi ...... ensitivity to PARP inhibitors.
@nl
type
label
PTEN deficiency in endometrioi ...... ensitivity to PARP inhibitors.
@en
PTEN deficiency in endometrioi ...... ensitivity to PARP inhibitors.
@nl
prefLabel
PTEN deficiency in endometrioi ...... ensitivity to PARP inhibitors.
@en
PTEN deficiency in endometrioi ...... ensitivity to PARP inhibitors.
@nl
P2093
P2860
P50
P1476
PTEN deficiency in endometrioi ...... ensitivity to PARP inhibitors.
@en
P2093
Alan Mackay
Ana M Mendes-Pereira
Daniel Wetterskog
Felipe C Geyer
Kay Savage
Konstantin J Dedes
Maryou B Lambros
Radost Vatcheva
P2860
P304
P356
10.1126/SCITRANSLMED.3001538
P407
P577
2010-10-01T00:00:00Z